Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Traditional Chinese Medicine for Treatment of Chronic Heart Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01939236
Recruitment Status : Completed
First Posted : September 11, 2013
Last Update Posted : October 10, 2013
Sponsor:
Collaborators:
Wuhan Hospital of Traditional Chinese Medicine
Zhengzhou Hospital of Traditional Chinese Medicine
Changchun University of Chinese Medicine
Hubei Hospital of Traditional Chinese Medicine
Yichang Hospital of Traditional Chinese Medicine
Dongzhimen Hospital, Beijing
Guang'an Men Hospital Affiliated to China Academy of Chinese Medicine Sciences
Information provided by (Responsible Party):
Wei Wang, Beijing University of Chinese Medicine

Brief Summary:
The purpose of this study is to determine whether traditional Chinese medicine as complementary treatment is safe and effective in the treatment of chronic heart failure.

Condition or disease Intervention/treatment Phase
Chronic Heart Failure Drug: traditional Chinese medicine Drug: Placebo (gummeline) Phase 2

Detailed Description:

Heart failure (HF) can be defined as an abnormality of cardiac structure or function leading to failure of heart to deliver oxygen at a rate commensurate with the requirements of the metabolizing tissues, despite normal filling pressures (or only at the expense of increased filling pressures). And according to the nature of the clinical presentation, HF is divided into acute or chronic HF.

In 2003, a random sample survey of 15,518 urban or rural residents between 35 and 74 years old was made in China: the prevalence rate of heart failure was 0.9%, and according to the result, there was about 4,000,000 HF subjects in China.

In China, the integrative treatment of western and traditional Chinese medicine (TCM) for HF is common and has been developed as a treatment model. TCM has been used in China and other south and east Asia countries for thousands of years. Syndrome differentiation and treatment variation are the basic principles in understanding and treatment of diseases. Investigators would like to test the hypothesis that it is efficacy and safety for patients to take TCM granules according to syndrome differentiation.

The specific aims for the study were to evaluate the efficacy and safety of TCM in treating chronic heart failure (CHF).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 220 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Traditional Chinese Medicine for Treatment of Chronic Heart Failure: A Multicenter Randomized Double-blind Placebo-controlled Clinical Trial
Study Start Date : May 2010
Actual Primary Completion Date : August 2012
Actual Study Completion Date : September 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Arm Intervention/treatment
Experimental: traditional Chinese medicine
Subjects were treated with TCM 2 times per day for 28 days according to syndrome differentiation. For example, the syndrome of one patient with chronic heart failure is qi deficiency and blood stasis. He will take drug of qi deficiency and blood stasis 2 times per day for 28 days.
Drug: traditional Chinese medicine
1 bag of drug 2 times per day for 28 days according to syndrome differentiation. For example, the syndrome of one patient is qi deficiency and blood stasis, he will take drugs of qi deficiency and blood stasis each bag 2 times per day for 28days.
Other Names:
  • Qi deficiency:huangqi, dangshen
  • Blood stasis: danshen, chishao,taoren, honghua
  • Water retention: zexie, zhuling, cheqianzi, tinglizi
  • Yang deficiency: rougui, zhifuzi

Placebo Comparator: placebo (gummeline)
Subjects were treated with placebo 2 times per day for 28 days according to syndrome differentiation. For example, the syndrome of one patient with chronic heart failure is qi deficiency and blood stasis. He will take drug of qi deficiency and blood stasis 2 times per day for 28 days.
Drug: Placebo (gummeline)

Placebo of each syndrome differentiation has the same weight and smell as traditional Chinese medicine of corresponding syndrome differentiation.

1 bag of drug 2 times per day for 28 days according to syndrome differentiation.

For example, the syndrome of one patient is qi deficiency and blood stasis, he will take drugs of qi deficiency and blood stasis each bag 2 times per day for 28 days.

Other Names:
  • Qi deficiency: gummeline
  • Blood stasis: gummeline
  • Water retention: gummeline
  • Yang deficiency: gummeline




Primary Outcome Measures :
  1. Left ventricular ejection fraction [ Time Frame: 14 days, 28 days ]
    The level of left ventricular ejection fraction was detected with the modified Simpson's rule at baseline and 28 days.


Secondary Outcome Measures :
  1. Traditional Chinese medicine syndrome scores (TCM-SS) [ Time Frame: 14 days, 28 days ]
    Before the study, all investigators took standardized training and conformance testing. Syndrome differentiation and syndrome scores were took by 3 investigators together, and the results needed to obtain two or more investigators' consent. There were 65 clinical symptoms evaluated as TCM symptoms, which was defined as TCM syndrome score. The standard of TCM symptoms scored as without 0; very light 1; light 2; medium 3; heavy 4; very heavy 5 points.

  2. New York Heart Association (NYHA) functional classification [ Time Frame: 14 days, 28 days ]
  3. 6-minute walk test (6MWT) [ Time Frame: 14 days, 28 days ]
    6MWT was took according to the guidelines for the 6MWT promulgated by the American Thoracic Society at baseline and 28 days after treatment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   45 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The basic primary heart disease is coronary heart disease ( with diagnosis for coronary heart disease : confirmed by coronary angiography; confirmed by coronary CT; history of acute myocardial infarction; limb-salvage Q wave for ECG; ecg ECG test and radionuclide examination support, etc.); no history of hypertension or taking antihypertensive drugs, with blood pressure under 160/100 mmHg.
  • With a history of coronary heart disease, symptoms and signs; with difficult breathing, fatigue and fluid retention (edema); with left ventricular enlargement, end systolic volume of left ventricular increase and left ventricular ejection fraction (LVEF) ≤ 40; with New York Heart Association (NYHA) functional classificationⅡ or Ⅲ.
  • Male or female subjects between 40 and 75 years old;

Exclusion Criteria:

  • Serious valvular heart disease, pericardial disease, cardiomyopathy, congenital heart disease, acute myocardial infarction ( within 4 weeks), cardiac shock, acute myocarditis or serious arrhythmia with the variation of hemodynamics.
  • Pulmonary artery hypertension caused by pulmonary heart disease, acute or chronic pulmonary embolism, or stroke within a half year.
  • Serious hepatic insufficiency ( the index of liver function being 2 times of normal one), renal insufficiency (Ccr>20%, Scr>3mg/dl or 265 μmol/L), diseases of blood system, malignant tumor, diabetes mellitus with serious complications, hyperthyroid or hypothyroid.
  • Infection: fever; the numeration of leukocyte being more than 10×109/L, the percentage of neutrophile granulocyte being more than 85%; patchy shadows in X ray of Chest, meeting one of the above three.
  • Pregnancy or lactation; mental disease and infectious disease patients.
  • Take part in other trials within two months.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01939236


Locations
Layout table for location information
China, Beijing
Beijing University of Chinese Medicine
Beijing, Beijing, China, 100029
Sponsors and Collaborators
Beijing University of Chinese Medicine
Wuhan Hospital of Traditional Chinese Medicine
Zhengzhou Hospital of Traditional Chinese Medicine
Changchun University of Chinese Medicine
Hubei Hospital of Traditional Chinese Medicine
Yichang Hospital of Traditional Chinese Medicine
Dongzhimen Hospital, Beijing
Guang'an Men Hospital Affiliated to China Academy of Chinese Medicine Sciences
Investigators
Layout table for investigator information
Study Chair: Wei Wang, Doctor Beijing University of Chinese Medicine
Principal Investigator: Peng Zhang, Doctor Wuhan Hospital of Chinese Medicine
Study Director: Huihui Zhao, Doctor Beijing University of Chinese Medicine
Principal Investigator: Liangtao Luo, Master Beijing University of Chinese Medicine

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Wei Wang, Vice-President, Beijing University of Chinese Medicine
ClinicalTrials.gov Identifier: NCT01939236     History of Changes
Other Study ID Numbers: BUCMlltllt1984
First Posted: September 11, 2013    Key Record Dates
Last Update Posted: October 10, 2013
Last Verified: October 2013

Keywords provided by Wei Wang, Beijing University of Chinese Medicine:
chronic heart failure
traditional Chinese medicine
syndrome differentiation

Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases